Imscin001 Part 2 Updated Results: Efficacy, Safety, Immunogenicity And Patient-Reported Outcomes (Pros) From The Randomised Phase Iii Study Of Atezolizumab (Atezo) Subcutaneous (Sc) Vs Intravenous (Iv) In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (Nsclc)
Atezolizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Imscin001 Part 2 Updated Results: Efficacy, Safety, Immunogenicity And Patient-Reported Outcomes (Pros) From The Randomised Phase Iii Study Of Atezolizumab (Atezo) Subcutaneous (Sc) Vs Intravenous (Iv) In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (Nsclc) ### Output: Atezolizumab